Corporate and Investment Developments Pertaining to Chardan Nextech Acquisition

Chardan Nextech Acquisition, listed on the New York Stock Exchange and denominated in U.S. dollars, has recently attracted new analyst coverage and participation in industry events. The company’s latest public disclosures include the initiation of coverage on two separate biopharmaceutical entities and a scheduled participation by Vicore Pharma Holding AB in a Chardan-hosted healthcare conference.

Analyst Coverage Initiatives

On 13 October 2026, Chardan Nextech Acquisition announced that it has begun coverage of Gossamer Bio Inc. (ticker: PAH) with an initial buy recommendation. The coverage highlights the potential of Gossamer Bio’s PAH therapy, implying a favorable view of the company’s product pipeline and market prospects. Simultaneously, the firm initiated coverage on Inhibikase Therapeutics Inc. (ticker: IBKI) with a neutral rating, suggesting an outlook that neither strongly supports nor opposes investment in the stock at this time.

These coverage decisions expand Chardan’s portfolio of biopharmaceutical investments and provide investors with new valuation and risk assessments for these entities.

Upcoming Industry Conference Participation

Vicore Pharma Holding AB, a clinical‑stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases, has confirmed its participation in the Chardan Healthcare Conference. The event will be held at the Lotte New York Palace on 20 October 2026, from 2:00 pm to 2:30 pm Eastern Time. Key elements of the conference include:

  • A panel discussion on idiopathic pulmonary fibrosis and chronic respiratory disease, covering antifibrotics, cystic fibrosis, bronchiectasis, and COPD innovation.
  • One‑on‑one meetings for detailed dialogue between industry stakeholders and company representatives.
  • Representation by Ahmed Mousa, CEO of Vicore Pharma, who will contribute to the panel.

Chardan’s organization of this conference underscores its role as a facilitator of dialogue within the biopharmaceutical sector, providing a platform for companies like Vicore to showcase their therapeutic developments to investors and clinicians.

Summary

The recent actions taken by Chardan Nextech Acquisition—initiating coverage on Gossamer Bio and Inhibikase Therapeutics and hosting a conference that includes Vicore Pharma—demonstrate an active engagement with the biopharmaceutical investment landscape. These developments offer investors new analytical perspectives and opportunities for direct interaction with emerging therapeutic candidates.